This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Sangamo Therapeutics Initiates Dosing in Hemophilia A Study
by Zacks Equity Research
Sangamo Therapeutics (SGMO) and partner Pfizer announced the dosing of first patient in Alta study on Hemophilia A candidate, SB-525.
Novartis (NVS) Receives EC Approval for Breast Cancer Drug
by Zacks Equity Research
Novartis AG (NVS) obtained approval for its breast cancer drug Kisqali in Europe.
Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug
by Arpita Dutt
It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.
Celldex Ends Phase II Enrollment for Breast Cancer Candidate
by Zacks Equity Research
Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment.
Roche (RHHBY) Hemophilia A Drug Granted Priority Review
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.
BioLineRx Moves a Regulatory Submission for BL-8040 Trial
by Zacks Equity Research
BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.
Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why
by Arpita Dutt
Late last week, Biogen (BIIB) and six other pharma and biotech stocks were in the news due to the pricing of their multiple sclerosis ("MS") drugs.
Mylan Finalizes Settlement Agreement with DOJ for $465M
by Zacks Equity Research
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.
Ophthotech's Fovista Combo Regimen Disappoints in Phase III
by Zacks Equity Research
Ophthotech (OPHT) disappoints with poor evaluation of Fovista combined with Eylea or Avastin for treatment of AMD in phase III. The study misses the primary endpoint.
Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.
Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus
by Zacks Equity Research
Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q2. Shares were down in after-hours trading.
Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View
by Zacks Equity Research
Mylan N.V. (MYL) reported disappointing second-quarter 2017 results wherein both earnings and sales missed estimates. The company also lowered its guidance.
Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inovio Pharmaceuticals (INO) reports narrower-than-expected loss with revenue beating estimates. Moreover, the top line significantly increases year over year.
Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment
by Zacks Equity Research
Prothena Corporation plc (PRTA) reported a narrower-than-expected loss in the second quarter as the company received a milestone payment from Roche.
Kite Pharma (KITE) Q2 Loss Narrower than Expected, Shares Up
by Zacks Equity Research
Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the second quarter of 2017 and beat estimates for sales. Shares of the biotech company rose 5.8% on Tuesday.
Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Epizyme, Inc. (EPZM) posted narrower-than-expected loss in Q2 as the company focuses on the development of tazemetostat.
What's in the Cards for Kite Pharma (KITE) in Q2 Earnings
by Zacks Equity Research
With no approved products in its portfolio, investor focus will primarily be on Kite Pharma, Inc.'s (KITE) cash burn and pipeline updates.
Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales
by Zacks Equity Research
Exelixis' (EXEL) second-quarter results were impressive where in both earnings and sales beat estimates driven by strong uptake of Cabometyx.
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Immune Design (IMDZ) incurred narrower-than-expected loss in Q2. Revenues missed expectations.
Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses
by Zacks Equity Research
Clovis Oncology (CLVS) reported narrower year-over-year loss in the second quarter on the back of impressive Rubraca sales. The company is also actively working on Rubraca's label expansion.
Mylan (MYL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Mylan N.V. (MYL) is expected to focus on the performance of EpiPen and progress with the biosimilars pipeline during its second-quarter results.
What to Expect from Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme, Inc. (EPZM) plans to focus on the development of its lead candidate tazemetostat in Q2.
Foreign Stock Roundup: GSK, Shell, AstraZeneca Beat on Earnings
by Swarup Gupta
Investors across the globe focused on earning numbers and the outcome of the Fed's policy meeting this week.
ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up
by Zacks Equity Research
ImmunoGen's (IMGN) Q2 results report a narrower-than-expected loss with revenue beating the estimates. The company also significantly raises the cash and revenue guidance this quarter.